Japan, March 5 -- BIOSION INC has got intellectual property rights for 'ANTIBODY BINDING SIGLEC15 AND USES THEREOF.' Other related details are as follows:
Application Number: JP,2023-172391
Category (FI): A61K39/395@N,A61P19/10,A61P35/00,C07K16/28,C12N1/15,C12N1/19,C12N1/21,C12N15/13,C12N15/63@Z,C12N5/10,C12P21/08
Stage: PROBLEM TO BE SOLVED: To provide a therapeutic approach for cancer patients unresponsive to PD-1/PD-L1 targeting therapies.SOLUTION: Provided herein is an isolated monoclonal antibody that specifically binds human Siglec15, or an antigen-binding portion thereof. Also provided are a nucleic acid molecule encoding the antibody or antigen-binding portion thereof, an expression vector, a host cell, and a method for expressing the antibody or antigen-binding portion thereof. The present disclosure further provides an immunoconjugate, a bispecific molecule, a chimeric antigen receptor, an oncolytic virus, and a pharmaceutical composition comprising the antibody or antigen-binding portion thereof, as well as a treatment method using the same.SELECTED DRAWING: None (Grant)
Filing Date: Oct. 3, 2023
Publication Date: Feb. 6, 2024
The original document can be viewed at: https://www.j-platpat.inpit.go.jp/p0100
Disclaimer: Curated by HT Syndication.
